ダラツムマブ
www.ema.europa.eu. 2019年6月4日閲覧。
↑ “Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma”. PLOS One 14 (2): e0211927. (2019). Bibcode: 2019PLoSO..1411927N. doi:10.1371/journal.pone.0211927. PMC 6374018. PMID 30759167. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374018/.
↑ “Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma”. Annals of Hematology 98 (8): 1999–2001. (2019). doi:10.1007/s00277-019-03645-7. PMID 30824957.
↑ “Evolving Role of Daratumumab: From Backbencher to Frontline Agent”. Clinical Lymphoma, Myeloma & Leukemia 20 (9): 572–587. (2020). doi:10.1016/j.clml.2020.03.